MedTrace Logo

A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)

NCT07640217 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-06-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of SYH2068 injection in patients with elevated lipoprotein(a).

Conditions

  • Adult Participants With Elevated Lipoprotein(a)

Interventions

DRUG

SYH2068 Dose 1

Administered by subcutaneous injection.

DRUG

SYH2068 Dose 2

Administered by subcutaneous injection.

DRUG

SYH2068 Dose 3

Administered by subcutaneous injection.

DRUG

Placebo

Administered by subcutaneous injection.

Sponsors & Collaborators

  • CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-30
Primary Completion
2028-03-30
Completion
2028-09-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07640217 on ClinicalTrials.gov